Pharmaceutical companies

Regulators Should Keep a Close Eye on the Little Guys in the Race for a Covid-19 Vaccine

As the race to find a Covid-19 vaccine or treatment rages on, many have raised concerns over trustworthiness of clinical research and...

Paid to Show the Drug Works: Why “Blind” Clinical Trials for New Drugs are Far Less Blind Than They Should Be

New research shows that physicians in industry-sponsored trials are more captured by pharmaceutical companies than physicians in unsponsored ones.

The Amazon of Health Care: How CVS Is Evolving From a Drug Store Chain into a Tech Platform

CVS is built on a dominant chain of drug stores, but it is now trying to turn itself into a "uniquely powerful platform" for...

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

Purdue's strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and...

Purdue Circumvented the Regulator to Promote OxyContin, Hiding Its Real Risk of Addiction

In 2001, the Food and Drug Administration required Purdue to change OxyContin’s patient package inserts to make addiction risks more evident. The company altered...

“Short Sellers Don't Exist to Fix the Problems. They Exist to Shed Light on the Problems”

In an interview with ProMarket, Fahmi Quadir, the short seller whose bet against Valeant in 2015 helped expose the company's misdeeds, talks about short...

Editors’ Briefing: On Our Radar This Week (March 3-March 10)

This week in political economy.     ProPublica has created a searchable database of 2,475 political appointees by the Trump administration, the result of “a year...

The "Secret" Driver of US Health Care Costs: Politicians Wanting to Get Reelected

A pioneering new study provides a first-of-its-kind look into the outsized effect that lobbying and political maneuverings have on health care spending.     Americans spend significantly more...

Perverse Market Incentives Encourage High Prescription Drug Prices

Pharmacy benefit managers (PBMs) are the under-discussed market participants who manage prescription drug insurance for the vast majority of Americans. PBMs claim to be a lone...

"The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology"

In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk...

LATEST NEWS

The Challenges to (Re)forming a Platform Economy for the People

Measured antitrust enforcement and a more comprehensive regulatory regime can ensure that we continue to benefit from digital markets. In attempting to...

Spectrum Auctions: There Is Elegance in the Mundane

As a student, Booth School Professor Anthony Lee Zhang was puzzled that Paul Milgrom chose to spend so much of his time...

Antitrust as Economic Stimulus

By attacking power imbalances, competition policy can steer income to workers and independent merchants who are more inclined to spend than monopoly...

The Monopolists and the Pandemic: What Covid-19 Teaches Us About Concentrated Power

In the preface of his new book Liberty from All Masters: The New American Autocracy vs. the Will of the People, Barry...

Bethany McLean’s Weekend Reading List: Insider Trading, Central Banking, and the Fall of the CDC

Corruption, lobbying, corporate malfeasance, and frauds: a weekly unconventional selection of must-read articles by investigative journalist Bethany McLean.